Clinical profile of prasugrel, a novel thienopyridine

American Heart Journal

Volumn 156, Issue 2 SUPPL., 2008, Pages 16S-22S

  Angiolillo, Dominick J ^a   Bates, Eric R ^b   Bass, Theodore A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IC 50; ISCHEMIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; RISK FACTOR; RISK REDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

EID: 47649132922     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.06.005     Document Type: Article

References (15)

1. Brandt J.T., Payne C.D., Wiviott S.D., et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153 (2007) 66.e9-66.e16
2. Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173
3. Sugidachi A., Ogawa T., Kurihara A., et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 5 (2007) 1545-1551
4. Jakubowski J.A., Matsushima N., Asai F., et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y(12) inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 63 (2007) 421-430
5. Jakubowski J.A., Payne C.D., Li Y.G., et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 99 (2008) 215-222
6. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12 receptor mediated platelet function than clopidogrel due to more efficient generation of its active metabolite in aspirin treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
7. Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
8. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 116 (2007) 2923-2932
9. Angiolillo D.J., Shoemaker S.B., Desai B., et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
10. von Beckerath N., Kastrati A., Wieczorek A., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28 (2007) 1814-1819
11. Varenhorst C., Baun O., James S., et al. Greater inhibition of platelet aggregation with a prasugrel 60 mg loading dose compared with a clopidogrel 600 mg loading dose in aspirin-treated patients. [abstract]. Eur Heart J 28 Suppl (2007) 189
12. Winters K.J., Payne C.D., Ernest C.S., et al. Prasugrel 60 mg versus clopidogrel 600 mg: greater platelet inhibition with prasugrel is explained by higher concentrations of the active metabolite. Eur Heart J 28 Suppl (2007) 218
13. Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152 (2006) 627-635
14. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
15. Wiviott S.D., Braunwald E., McCabe C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 371 (2008) 1353-1363